Quick Answer
UroGen Pharma Ltd. reported Gross Profit of $97.34 million for the year ending 2025.
- UroGen Pharma Ltd. showed an increase of +19.4% in Gross Profit from 2024 to 2025.
- This data is from UroGen Pharma Ltd.'s annual report (Form 10-K), filed with the SEC on March 2, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: $51.0 thousand | Q2 2018: $46.0 thousand | Q3 2018: -$772.0 thousand | Q2 2019: $18.0 thousand | Q2 2020: $324.0 thousand | Q3 2020: $3.15 million | Q1 2021: $6.59 million | Q2 2021: $11.61 million | Q3 2021: $10.11 million | Q1 2022: $12.04 million | Q2 2022: $14.76 million | Q3 2022: $14.08 million | Q1 2023: $14.93 million | Q2 2023: $18.70 million | Q3 2023: $18.49 million | Q4 2023: $21.24 million | Q1 2024: $17.05 million | Q2 2024: $19.62 million | Q3 2024: $22.75 million | Q4 2024: $22.09 million | Q1 2025: $17.92 million | Q2 2025: $20.67 million | Q3 2025: $24.20 million.
- Over the full 10 years of available data (2016 to 2025), UroGen Pharma Ltd.'s Gross Profit has grown by 456.2%.
- Historical annual values: Fiscal year 2025: $97.34 million | Fiscal year 2024: $81.52 million | Fiscal year 2023: $73.35 million | Fiscal year 2022: $56.70 million | Fiscal year 2021: $42.89 million | Fiscal year 2020: $10.79 million | Fiscal year 2019: $18.0 thousand | Fiscal year 2018: -$675.0 thousand | Fiscal year 2017: $7.56 million | Fiscal year 2016: $17.50 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: